awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35943654-5C6F3510-4CDD-4D3C-B831-2A45061F4E6B
Q35943654-5C6F3510-4CDD-4D3C-B831-2A45061F4E6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35943654-5C6F3510-4CDD-4D3C-B831-2A45061F4E6B
Dose-dense temozolomide: is it still promising?
P2860
Q35943654-5C6F3510-4CDD-4D3C-B831-2A45061F4E6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35943654-5C6F3510-4CDD-4D3C-B831-2A45061F4E6B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ff21ccdec6673b5d072c2b21cc89cd0d5e2ae96d
P2860
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.